Mechanisms of resistance to JAK inhibitors. L. Knoops
|
|
- Isaac Bradley
- 6 years ago
- Views:
Transcription
1 Mechanisms of resistance to JAK inhibitors L. Knoops
2 1 : Resistance to tyrosine kinase inhibition in cancer
3 are related in sequence and structure. The main diagram illustrates the similarity between the protein sequences of these catalytic domains. Each kinase is at the tip of a branch, and the similarity between various kinases is inversely related to the distance between their positions on the tree diagram. Most kinases fall into small families of highly related sequences, and most Tyrosine kinases THE FGFR2 FGFR3 EphB2 EphA3 FGFR4 TRKA EphB1 EphA5 FGFR1 TRKB DDR2 DDR1 EphA4 EphA6 Yes IRR Ros ALK LTK Fyn FLT1 KDR Fms/CSFR Kit Ret Tyro3/ Sky RYK EphA8 CCK4/PTK7 TK Ack Tnk1 HER3 EphA2 BLK ITK FRK CTK CSK Arg Abl Srm Brk HER4 Tyk2 JAK1 JAK2 JAK3 ANKRD3 SgK288 ZAP70 PYK2 Syk FAK EphA1 TEC TXK BTK Etk/BMX EGFR HER2 TIE2 TIE1 Fgr Lck FLT4 PDGFR" FLT3 PDGFR% Met Ron EphB4 EphA7 Tyrosine Kinase inhibitors Mer Axl IGF1R InsR Src Lyn HCK ROR2 ROR1 MuSK EphB3 H Tyrosine Kinase inhibitors TRKC Lmr1 Lmr2 ZA EphB6 RIPK2 Lmr3 IRAK3 IRAK1 EphA10 RIPK3 LIMK1 LIMK2 TESK1 TESK IRAK2 Fes Fer ANP" ANP% JAK3~b JAK2~b Tyk2~b JAK1~b RIPK1 LRRK2 LRRK1 SuRTK106 IRAK4 MOS HSER DYRK2 SgK496 PBK
4 Tyrosine kinase inhibitors cabl kinase domain cristal strucure with imatinib Adapted from Nagar et al, Cancer Res, 2002
5 Tyrosine kinase inhibitors cabl kinase domain cristal strucure with imatinib Adapted from Nagar et al, Cancer Res, 2002
6 Tyrosine kinase inhibitors in cancer Mutant Clone Resistant clone WT TKI Resistance time
7 are related in sequence and structure. The main diagram illustrates the similarity between the protein sequences of these catalytic domains. Each kinase is at the tip of a branch, and the similarity between various kinases is inversely related to the distance between their positions on the tree diagram. Most kinases fall into small families of highly related sequences, and most Tyrosine kinases THE FGFR2 FGFR3 EphB2 EphA3 FGFR4 TRKA EphB1 EphA5 FGFR1 TRKB DDR2 DDR1 EphA4 EphA6 Yes IRR Ros ALK LTK Fyn FLT1 KDR Fms/CSFR Kit Ret Tyro3/ Sky TIE2 TIE1 CCK4/PTK7 Fgr TK Ack Tnk1 HER3 EphA2 BLK ITK FRK CTK CSK Arg Abl Srm Brk Resistance? HER4 Tyk2 JAK1 JAK2 JAK3 ANKRD3 SgK288 ZAP70 PYK2 Syk FAK EphA1 TEC TXK BTK Etk/BMX EGFR HER2 RYK EphA8 Lck FLT4 PDGFR" FLT3 PDGFR% Met Ron EphB4 EphA7 Tyrosine Kinase inhibitors Mer Axl IGF1R InsR Src Lyn HCK ROR2 ROR1 MuSK EphB3 H Tyrosine Kinase inhibitors TRKC Lmr1 Lmr2 ZA EphB6 RIPK2 Lmr3 IRAK3 IRAK1 EphA10 RIPK3 LIMK1 LIMK2 TESK1 TESK IRAK2 Fes Fer ANP" ANP% JAK3~b JAK2~b Tyk2~b JAK1~b RIPK1 LRRK2 LRRK1 SuRTK106 IRAK4 MOS HSER DYRK2 SgK496 PBK
8 JAK2 kinase domain ABL kinase domain JAK2 kinase domain cabl kinase domain cristal strucure with imatinib JAK2 kinase domain cristal structure with CP Adapted from Nagar et al, Cancer Res, 2002;Williams et al, J Mol Biol, 2009
9 JAK2 kinase domain ABL kinase domain JAK2 kinase domain cabl kinase domain cristal strucure with imatinib JAK2 kinase domain cristal structure with CP Adapted from Nagar et al, Cancer Res, 2002;Williams et al, J Mol Biol, 2009
10 JAK2 kinase domain ABL kinase domain JAK2 kinase domain cabl kinase domain cristal strucure with imatinib JAK2 kinase domain cristal structure with CP Adapted from Nagar et al, Cancer Res, 2002;Williams et al, J Mol Biol, 2009
11 JAK Kinases FERM PSEUDO- KINASE DOMAIN KINASE DOMAIN N C Adapted from Giordanette F et al, Protein Eng, 2002 V617F
12 JAK2 V617F model JAK2 JH1-JH2 domains model Adapted from Giordanetto et al, Protein Eng, 2002
13 Cytokine Cytokine receptors signal transduction Cytokine Cytokine Y JAK JAK Y P! Y JAK JAK Y P! P! Y JAK JAK Y P! Y Y Y Y P! Y Y P! Y Y Y Y P! Y Y P! STAT P!Y Y P! STAT JAK-STAT STAT P!Y Y P! STAT
14 Cytokine receptors signal transduction Cytokine RAS JAK JAK P! Y Y P! P! Y Y P! P! Y Y P! MAPKinase PI3Kinase STAT P!Y Y P! STAT JAK-STAT STAT P!Y Y P! STAT
15 Cytokine receptors signal transduction Cytokine 50 cytokine receptors P! Y JAK JAK Y P! P! Y Y P! 4 JAKs P! Y Y P! Homo or heterodimers
16 Cytokine receptors using JAK2 Homodimeric ßc Type II IFN EPO, TPO, GH, PRL IL-3, 5, GM-CSF IFNγ ßc JAK2 JAK2 JAK2 JAK2 JAK1 JAK2 STAT5 STAT5 STAT1
17 Cytokine receptors using JAK1 γc gp130 Type I IFN Type II IFN IL-2, 4, 7, 9, 15, 21 IL-6, G-CSF, OSM IFNa, ß IFNγ γc gp130 JAK1 JAK3 JAK1 TYK2 JAK1 TYK2 JAK1 JAK2 STAT5 STAT3 STAT6 STAT3 STAT1 STAT2 STAT1
18 1 : Resistance to tyrosine kinase inhibition in cancer - JAK inhibitors are ATP-competitive inhibitors - JAK inhibitors are not imatinib!. Not specific for mutated vs WT JAKs. JAK inhibition will interfere with many cytokine receptors 2 : In vitro mechanisms of JAK inhibitor resistance
19 IL-9 R signal transduction IL- 9R signal transduc3on
20 IL-9 R phe116 receptor
21 In vitro model of tumorigenesis JAK1 overexpression JAK1 mutations IL-9 IL-9 / / BaF3 phe116 IL-9 responding Autonomous
22 JAK1 JH1-JH2 domains model JAK1 activating mutations
23 JAK1 activating mutations Mutated residues V658F, L, I JAK1 JH1-JH2 domains model
24 JAK1 activating mutations Mutated residues JAK1 JH1-JH2 domains model
25 JAK1 activating mutations Mutated residues JAK1 JH1-JH2 domains model
26 JAK1 activating mutations Mutated residues Mutated residues in ALL JAK1 JH1-JH2 domains model Flex et al., 2008, Asnafi et al., 2008, Jeong et al., 2008, Mullighan et al., 2009
27 JAK1 activating mutations : kinase domain JAK1 kinase domain cristal structure with CP Adapted from Williams et al., J.Mol.Biol, 2009
28 JAK1 F958V is resistant to JAK inhibitor I Western Blot Hornakova et al, Haematologica, 2011
29 JAK1 F958V is resistant to Ruxolitinib 120 Proliferation (% of control) 100 M-RAS Aut(F958V) 40 Aut(V658F) Ruxolitinib (µm) BaF3 cells - H3 thymidine incorporation Hornakova et al, Haematologica, 2011
30 Prolonged treatment with JAK inhibitor induces JAK1 overexpression Quantitative PCR Hornakova et al, Haematologica, 2011
31 JAK1 and ABL1 hinge regions P960T/S F958V/C/S/L (JAK inhibitors) JAK1 925 KLIMEFLPSGSLKEYLPK-NKN 973.:. :.. :.:.: :. ABL1 312 YIITEFMTYGNLLDYLRECNRQ 333 T315I/A/S (Imatinib) E316D F317L/I M318A G321V Crystal structure of JAK1, JAK2 and ABL Hornakova et al, Haematologica, 2011
32 The JAK2 Y931C mutation induces resistance to ruxolitinib 120 Proliferation (in % of control) V617F Y931C V617F/Y931C Ruxolitinib (um) BaF3 cells - H3 thymidine incorporation Hornakova et al, Haematologica, 2011
33 JAK2 kinase domain mutations resistant to JAK inhibitors Activating and resistant mutations Resistant mutations E864A Y931C G935R Hornakova et al, Haematologica, 2011 Weigert et al, J Exp Med, 2012 JAK2 kinase domain cristal structure with CP Adapted from Williams et al., J.Mol.Biol, 2009
34 1 : Resistance to tyrosine kinase inhibition in cancer - JAK inhibitors are ATP-competitive inhibitors - JAK inhibitors are not imatinib!. Not specific for mutated vs WT JAKs. JAK inhibition will interfere with many cytokine receptors 2 : In vitro mechanisms of JAK inhibitor resistance - JAK inhibitors are able to kill JAK-dependent cells - JAK kinase domain mutation and overexpression can explain resistance 3 : Clinical resistance to JAK inhibitors in MF
35 COMFORT-II : Percent change from baseline in spleen volume 80 At Week 48 Patient characteristics? % Change from baseline at week Ruxoli3nib P <.0001 Primary endpoint - 80 Ruxoli3nib BAT Harrison C, ASH 2011, Abstract 279
36 1 : Resistance to tyrosine kinase inhibition in cancer - JAK inhibitors are ATP-competitive inhibitors - JAK inhibitors are not imatinib!. Not specific for mutated vs WT JAKs. JAK inhibition will interfere with many cytokine receptors 2 : In vitro mechanisms of JAK inhibitor resistance - JAK inhibitors are able to kill JAK-dependent cells - JAK kinase domain mutation and overexpression can explain resistance 3 : Clinical resistance to JAK inhibitors in MF - Clinical resistance exists Mainly primary resistance (short follow-up) 4 : Molecular resistance to JAK inhibitors in MF
37 Tyrosine kinase inhibitors in cancer Mutant Clone Resistant clone WT TKI Resistance time
38 JAK kinases inhibitors in PMF WT JAK2 V617F + JAK2 V617F + WT TKI time
39 JAK kinases inhibitors in PMF WT JAK2 V617F + JAK2 V617F + WT TKI time
40 Potential cause of JAK2 V617F persistance Is the JAK2 V617F MPN clone addicted to JAK-STAT signaling? 120 Proliferation (in % of control) JAK2 V617F M Ras Ruxolitinib (um)
41 JAK kinases inhibitors in PMF JAK2 V617F + JAK2 V617F + WT WT TKI time
42 Potential cause of JAK2 V617F persistance 120 Proliferation (in % of control) JAK2 V617F M Ras Normal hematopoiesis JAK2 V617F persistance Ruxolitinib (um) Toxic dose
43 1 : Resistance to tyrosine kinase inhibition in cancer - JAK inhibitors are ATP-competitive inhibitors - JAK inhibitors are not imatinib!. Not specific for mutated vs WT JAKs. JAK inhibition will interfere with many cytokine receptors 2 : In vitro mechanisms of JAK inhibitor resistance - JAK inhibitors are able to kill JAK-dependent cells - JAK kinase domain mutation and overexpression can explain resistance 3 : Clinical resistance to JAK inhibitors in MF - Clinical resistance exists Mainly primary resistance (short follow-up) 4 : Molecular resistance to JAK inhibitors in MF
44 1 : Resistance to tyrosine kinase inhibition in cancer - JAK inhibitors are ATP-competitive inhibitors - JAK inhibitors are not imatinib!. Not specific for mutated vs WT JAKs. JAK inhibition will interfere with many cytokine receptors 2 : In vitro mechanisms of JAK inhibitor resistance - JAK inhibitors are able to kill JAK-dependent cells - JAK kinase domain mutation and overexpression can explain resistance 3 : Clinical resistance to JAK inhibitors in MF - Clinical resistance exists Mainly primary resistance (short follow-up) 4 : Molecular resistance to JAK inhibitors in MF - No JAK kinase signaling addiction vs effective dose too toxic
45 JAK2 V617F + Better inhibitors? WT WT TKI time
46 Thanks J.C. Renauld T. Hornakova L. Springuel A. Saumet SN Constantinescu C. Hermans E. Van den neste L. Michaux M.C. Vekemans V. Havelange X. Poiré C. Lambert A. Ferrant
Supplementary information
Supplementary information Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis I-Che Chung 1, Chun-Nan OuYang 1, Sheng-Ning Yuan 1,
More informationFor Simultaneously Detecting the Relative Level of Tyrosine Phosphorylation of Human Receptor Tyrosine Kinases (RTKs).
RayBio Phosphorylation Antibody Array I For Simultaneously Detecting the Relative Level of Tyrosine Phosphorylation of Human Receptor Tyrosine Kinases (RTKs). User Manual (Revised Jul 25, 2007) (Cat# AAH-PRTK-1-2;
More informationOvercoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding
Supplementary Information Overcoming Resistance to Inhibitors Through State-Specific Kinase Binding Chris J. Novotny 1, Sirkku Pollari 2, Jin H. Park 3, Mark A. Lemmon 3,4, Weijun Shen 2*, Kevan M. Shokat
More informationSupplemental text file, including:
Supplemental text file, including: Supplemental Table S1: Kinase profile for XL147 Supplemental Table S2: Effects of XL147 on PI3K Pathway Signaling in MCF7 and PC-3 Cells Supplemental Table S3: XL147
More informationSupplementary Information. Targeting BRK-positive Breast Cancer with Small
Supplementary Information Targeting BRK-positive Breast Cancer with Small Molecule Kinase Inhibitors Jie Jiang 1#, Fu Gui 1#, Zhixiang He 1#, Li Li 1, Yunzhan Li 1, Shunying Li 2, Xinrui Wu 1, Zhou Deng
More informationSupplementary Materials for
Electronic Supplementary Material (ESI) for Integrative Biology. This journal is The Royal Society of Chemistry 217 Supplementary Materials for Chemical genomic analysis of GPR35 signaling Heidi (Haibei)
More informationSupplementary Table 1. In vitro side effect profiling study for LDN/OSU
Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Receptor Percent Inhibition 10 µm Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective
More informationProtein tyrosine kinase signaling
rotein tyrosine kinase signaling Serge ROCHE CRBM CNRS/Montpellier University serge.roche@crbm.cnrs.fr rotein phosphorylation on Tyr A central mechanism to control cell communication in a multicellular
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/322/ra38/dc1 Supplementary Materials for Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer Andrea
More informationSupplementary information S1 (table): Specifications of individual protein protein interactions within the Cbl and Cbl-b interactomes
Supplementary information S1 (table): Specifications of individual protein protein interactions within the Cbl and Cbl-b interactomes Cbl/Cbl-b binding protein Cbl domain/residue Binding protein domain/residue
More informationNanoBRET: A Quantitative Technique to Measure Kinase Target Engagement in Live Cells Matthew Robers
anobret: A Quantitative Technique to Measure Kinase Target Engagement in Live Cells Matthew Robers Sr. Research Scientist & Group Leader Premise: Targets may behave differently in cells than in isolation
More information50 nmoles substrate. 8,000 Test Points based on 100 nm in reaction
Product Insert IMAP Substrates About the IMAP Substrates To facilitate the customization of the IMAP assay to fit your specific needs, Molecular Devices offers a wide range of validated substrates and
More informationBrigatinib overcomes ALK resistance mechanisms preclinically Zhang et al Supplementary information
Supplementary information The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models Sen Zhang, Rana Anjum, Rachel
More informationJakinibs 101: Theory, Practice and Prospects. References 10/27/2013
Jakinibs 101: Theory, Practice and Prospects As a rheumatologist, what do you need to know? Why should you care? Understand what Jaks are Which cytokines care, which don t Mechanisms underlying Jakinib
More informationSupplemental Table S1: Inhibition of HDAC class I and class II family by CUDC-101 (IC50 in nm)
Supplemental Table S1: Inhibition of HDAC class I and class II family by CUDC-101 (IC50 in nm) Class I Class II HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC6 HDAC7 HDAC9 HDAC10 4.5 12.6 9.1 79.8 13.2 11.4
More informationHow to compute a semantic similarity threshold. Charles Bettembourg, Christian Diot, Olivier Dameron
How to compute a semantic similarity threshold Charles Bettembourg, Christian Diot, Olivier Dameron Abstract The analysis of gene annotations related to Gene Ontology plays an important role in the interpretation
More informationOrigin of oncogenes? Oncogenes and Proto-oncogenes. Jekyll and Hyde. Oncogene hypothesis. Retroviral oncogenes and cell proto-oncogenes
Oncogenes and Proto-oncogenes Jekyll and Hyde A double edged sword Origin of oncogenes? Oncogene hypothesis Retroviral oncogenes and cell proto-oncogenes (v-onc) (c-onc) The role of c-onc in cancer How
More informationRXDX-101 & RXDX-102. Justin Gainor, MD February 20 th, 2014
RXDX-101 & RXDX-102 Justin Gainor, MD February 20 th, 2014 Background Chromosomal fusions are important oncogenic drivers in NSCLC - ALK Rearrangements (4-6%) - ROS1 Rearrangements (1-2%) - RET Rearrangements
More informationBCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid
Supplementary Results BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia Oliver Hantschel*, Wolfgang Warsch*, Eva Eckelhart*, Ines Kaupe, Florian Grebien, Kay-Uwe Wagner, Giulio
More informationHoward Temin. Predicted RSV converted its genome into DNA to become part of host chromosome; later discovered reverse transciptase.
Howard Temin Predicted RSV converted its genome into DNA to become part of host chromosome; later discovered reverse transciptase Nobel prize 1975 Figure 3.6 The Biology of Cancer ( Garland Science 2007)
More informationWhat can we learn from PAH patients with normalised pulmonary vascular resistance on treatment?
DHU Thorax Innovation What can we learn from PAH patients with normalised pulmonary vascular resistance on treatment? Marc HUMBERT, MD, PhD UMRS 999 INSERM Université Paris Sud DHU Thorax Innovation (TORINO),
More informationRole of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
Siveen et al. Molecular Cancer (2018) 17:31 https://doi.org/10.1186/s12943-018-0788-y REVIEW Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products Open
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:.38/nature83 Supplementary figure An Overview of Experimental Flow Hypothesis: The tumor microenvironment has a significant impact on cancer cell chemoresistance. Screen Coculture
More informationOncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors Tekla Hornakova, 1,2 Lorraine Springuel, 1,2 Julien Devreux, 1,2 Alexandra Dusa, 1,2 Stefan N. Constantinescu, 1,2 Laurent
More informationSUPPLEMENTAL DATA. Supplemental Experimental Procedures
SUPPLEMENTAL DATA An ATP-competitive mtor inhibitor reveals rapamycin-resistant functions of mtorc1 Carson C. Thoreen, Seong A. Kang, Jae Won Chang, Qingsong Liu, Jianming Zhang, Yi Gao, Laurie J. Reichling,
More informationSupplementary Data Figure S1. A) PKI-587 suppression of p-akt in A498 and (+/- 10
Supplementary Data Figure S1. A) PKI-587 suppression of p-akt in A498 and 786-0 (+/- 10 μm Verapamil), and B) PKI-587 suppression of p-akt in BT474, & U87MG. 3 1 0.3 0.1 0.03 0 [μm] A) 786-0 - + p-akt
More informationOncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
Published Ahead of of Print on on March April 1, 10, 2011, as as doi:10.3324/haematol.2010.036350. Copyright 2011 Ferrata Storti Foundation. Early Release Paper Oncogenic JAK1 and JAK2-activating mutations
More informationStructural modeling of JAK1 mutations in T-ALL reveals a second contact site between pseudokinase and kinase domains
Published Ahead of Print on January 27, 2016, as doi:10.3324/haematol.2015.138248. Copyright 2016 Ferrata Storti Foundation. Structural modeling of JAK1 mutations in T-ALL reveals a second contact site
More informationIncorporation of photo-caged lysine (pc-lys) at K273 of human LCK allows specific control of the enzyme activity.
Supplementary Figure 1 Incorporation of photo-caged lysine (pc-lys) at K273 of human LCK allows specific control of the enzyme activity. (a) Modeling of the kinase domain of LCK with ATP (left) or pc-lys
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S3 TAM- family small molecule kinase inhibitors in development Compound Indication(s) Target Profile Develop Primary Target MERTK TYRO3 Other targets ment Phase Refs Cabozantinib
More informationSupplemental Table 1. Biochemical and Cellular Potency and Selectivity of PF
Supplemental Table 1. Biochemical and Cellular Potency and Selectivity of PF- 02341066 Assay IC 50 nm Selectivity Ratio d Biochemical Activity In Vitro c-met/hgfr enzyme (Ki, nm) a 4 NA Cellular Activity
More informationSupporting Information
Supporting Information Bommi-Reddy et al. 10.1073/pnas.0806574105 Fig. S1. Reintroducing wild-type pvhl in VHL / cells does not affect cell growth in vitro.(a) Immunoblot analysis of 786-O and RCC4 VHL
More informationVEGFR. 1
VEGFR VEGFRs (vascular endothelial growth factor receptors) are tyrosine kinase receptors responsible for binding with VEGF to initiate signal cascades that stimulate angiogenesis among other effects.
More informationSupplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines.
Supplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines. The scores summarize the global expression of the tissue
More informationSignaling Through Immune System Receptors (Ch. 7)
Signaling Through Immune System Receptors (Ch. 7) 1. General principles of signal transduction and propagation. 2. Antigen receptor signaling and lymphocyte activation. 3. Other receptors and signaling
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationSupplementary information. Supplementary Table 1. Kinase Type Format N Average (IC 50 )
Supplementary information Supplementary Table 1 Kinase Type Format N Average (IC 50 ) SD ALK Y Lantha 6 > 10 n.d. AURORA_A S/T Caliper 6 > 10 n.d. AXL Y Lantha 3 > 10 n.d. BTK Y Caliper 6 > 10 n.d. cabl
More information2. Appendix Tables legend General Legend applicable for Table S1 to S4 (Page 10)
Appendix Data The hvps- signalling module counteracts inhibition of the PIK-Akt pathway to maintain mtorc activity and tumour growth Ruzica Bago, Eeva Sommer, Pau Castel, Claire Crafter, Fiona P. Bailey,
More informationChi sono i candidati agli inibitori di JAK2
Chi sono i candidati agli inibitori di JAK2 Francesco Passamon, Hematology, University Hospital Varese, Italy Ruxoli8nib (US approved in MF; EAP study and compassionate use in Italy) SAR302503 (phase 3
More information(12) United States Patent (10) Patent No.: US 8.461,161 B2
US008461161 B2 (12) United States Patent (10) Patent No.: US 8.461,161 B2 Burns et al. (45) Date of Patent: *Jun. 11, 2013 (54) SUBSTITUTED PYRAZINES AS INHIBITORS (56) References Cited OF KINASE ACTIVITY
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
REVIEW ARTICLE JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Lorraine Springuel, 1,2 Jean-Christophe Renauld,
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationTargeted Therapies: Radiosensitizing Effects of Kinase Inhibitors
Targeted Therapies: Radiosensitizing Effects of Kinase Inhibitors Molecular and Clinical Radiobiology Workshop McGill University Health Centre, June 17-19, 2015 Bertrand J. Jean-Claude, PhD Associate Professor,
More informationSUPPLEMENTAL TABLES. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
SUPPLEMENTAL TABLES Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Ping Chen 1, Nathan V. Lee 2, Wenyue Hu 3, Meirong Xu 2, Rose Ann Ferre 1, Hieu Lam 2, Simon Bergqvist 2,
More informationStaurosporine Tethered Peptide Ligands for camp-dependent Protein Kinase A (PKA): Optimization and Selectivity Profiling
Staurosporine Tethered Peptide Ligands for camp-dependent Protein Kinase A (PKA): Optimization and Selectivity Profiling Carolyn D. Shomin, Scott C. Meyer and Indraneel Ghosh* Supplementary Information
More informationContent Prioritization And Content Entry and Quality Control Process
Content Prioritization And Content Entry and Quality Control Process The process of data capture begins with the definition of the content module or sub-module to be built (see figure 1). Broadly we define
More informationNieuwe targets en cfdna
Nieuwe targets en cfdna dr. A.J. van der Wekken Universitair Medische Centrum Groningen Leek meeting 2017 Disclosure Advisory board: Lilly Boehringer-Ingelheim Pfizer AstraZeneca MSD Lectures: Lilly Boehringer-Ingelheim
More informationLight-assisted small molecule screening against
SUPPLEMENTARY INFORMATION Light-assisted small molecule screening against protein kinases Álvaro Inglés-Prieto 1, Eva Reichhart 1, Markus K. Muellner 2, Sebastian M. Nijman 2,4, Michael Grusch 3 & Harald
More informationReview Article The Role of Suppressors of Cytokine Signalling in Human Neoplasms
Molecular Biology International, Article ID 630797, 24 pages http://dx.doi.org/10.1155/2014/630797 Review Article The Role of Suppressors of Cytokine Signalling in Human Neoplasms Walid Sasi, 1 Anup K.
More informationHojjat-Farsangi, Mohammad DOI: / X
This is an author produced version of a paper published by Journal of Drug Targeting. This paper has been peerreviewed but does not include the final publisher proofcorrections or journal pagination. Targeting
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More information-X S.S. N1. (12) United States Patent US 9,029,386 B2. May 12, (45) Date of Patent: (10) Patent No.: (63) Burns et al.
USOO9029386B2 (12) United States Patent Burns et al. (10) Patent No.: (45) Date of Patent: US 9,029,386 B2 May 12, 2015 (54) (71) (72) (73) (*) (21) (22) (65) (63) (60) (30) (51) (52) PYRONEDERVATIVESUSEFULAS
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationDesigner Affinity Reagents. Brian Kay
Designer Affinity Reagents Brian Kay bkay@uic.edu Types of Affinity Reagents Src SH3 domain Lysozyme Src SH3 domain FN3 monobody Peptide Ligand Antibody Fragment Scaffold M13 Bacteriophage 900 nm x 10
More informationMECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D.
MECHANISMS OF 1ST GENERATION RESISTANCE Byoung Chul Cho, M.D., Ph.D. CONFLICT OF INTEREST Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST Consulting role: Novartis, AstraZeneca,
More informationDesigner Affinity Reagents. Reagents. Types of Affinity. M13 Bacteriophage. 900 nm x 10 nm. Brian Kay Src SH3 domain.
Designer Affinity Reagents Brian Kay bkay@uic.edu Types of Affinity Reagents Src SH3 domain Lysozyme Src SH3 domain FN3 monobody Peptide Ligand Antibody Fragment Scaffold M13 Bacteriophage 900 nm 10 nm
More informationTKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology
TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients Moustafa Sameer Hematology Medical Advsior,Novartis oncology Introduction In people with chronic myeloid leukemia, A
More informationPost-ASH 2015 CML - MPN
Post-ASH 2015 CML - MPN Fleur Samantha Benghiat, MD, PhD Hôpital Erasme, Brussels 09.01.2016 1. CML CML 1st line ttt Prognosis Imatinib Nilotinib Response Discontinuation Dasatinib Low RISK PROFILE High
More information2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors
SUPPORTING INFORMATION 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors Leena Patel,* Jayaraman Chandrasekhar, Jerry Evarts, Aaron C. Haran, Carmen Ip, Joshua
More informationThe Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition. Thomas Bertrand PSDI 2012
The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition Thomas Bertrand PSDI 2012 1 Trk (tropomyosin related kinases*) family: 3 receptor tyrosine kinases TrkA, TrkB,
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationThe g c Family of Cytokines Prof. Warren J. Leonard M.D.
The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services
More informationMPNs: JAK2 inhibitors & beyond. Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt
MPNs: JAK2 inhibitors & beyond Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt Myeloproliferative Neoplasms (MPNs) AGENDA: 1. Molecular biology 2. New WHO diagnostic criteria. 3. Risk stratification
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationBiomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems
Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems Volume 4 For further volumes: http://www.springer.com/series/10155 Marc Thiriet Intracellular Signaling Mediators in
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationYong Wu, Ph.D. Division of Cancer Research and Training (DCRT) Charles R. Drew University of Medicine & Science
Yong Wu, Ph.D. Division of Cancer Research and Training (DCRT) Charles R. Drew University of Medicine & Science Jay Vadgama, Ph.D Chief, Division of Cancer Research and Training Background One in 8 women
More informationMALATTIE MIELOPROLIFERATIVE CRONICHE
MALATTIE MIELOPROLIFERATIVE CRONICHE Dott. Roberto Latagliata Policlinico Umberto I Università Sapienza, Roma Highlights from EHA 2017: some points to address today WHO 2016 MPN classification: hot topics
More informationRegulatory Status FDA-approved indication: Cabometyx is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.79 Subject: Cabometyx Page: 1 of 5 Last Review Date: March 16, 2018 Cabometyx Description Cabometyx
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationDepartment of Chemistry, University of Washington, Seattle, Washington 98195, United States *S Supporting Information
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. pubs.acs.org/biochemistry
More informationBlocking c-met mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
CORRECTION NOTICE Nat. Med. 22, 194 21 (216) Blocking mediated phosphorylation enhances anti-tumor effects of PARP inhibitors Yi Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L Hsu, Hung-Ling Wang, Yi-Hsin
More informationT Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009
T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationJAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Degryse and Cools Journal of Hematology & Oncology (2015) 8:91 DOI 10.1186/s13045-015-0192-7 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH HIGHLIGHT JAK kinase inhibitors for the treatment of acute lymphoblastic
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationWHY TARGETTING SIGNALLING PATHWAYS?
WHY TARGETTING SIGNALLING PATHWAYS? Cancer cells are particularly sensitive to stress therefore sensitive to inhibition of their hyper activated signaling proteins the re instatement of lost tumor suppressors.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in
More informationASCO 2011: Leukemia. Disclosures
ASCO 2011: Leukemia E.J. Feldman M.D Weill-Cornell Medical College Disclosures Speaker does not report any affiliations 1 V617F JAK2 mutation in MPDs JAK STAT PATHWAY Signal transducers and activators
More informationJAK inhibitors in Phmyeloproliferative
Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationJAK-STAT signaling: clinicopathology and therapeutics. Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016
JAK-STAT signaling: clinicopathology and therapeutics Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016 Questions? Outline the canonical steps in JAK-STAT signalling pathways? What is the clinical
More informationWinship Cancer Institute of Emory University New Determinants and Approaches for MPN
Winship Cancer Institute of Emory University New Determinants and Approaches for MPN Elliott F. Winton August 8, 2014 Sea Island, Georgia Outline: MPN Determinants, Approaches Diagnosis Prognosis Treatment
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
More informationDMSO GNF7156 GNF4877 DA/ U Ed/ nilusni M o u s e b e t a c e l l p r o li f e r a t i o n GNF4877 G N F G N F Ki6 e 3
GNF4877 Vehicle % E d u + In s + c e lls Insulin/ Ki67 Insulin/EdU/DAPI a b DMSO GNF7156 GNF4877 c d M o u s e b e ta c e ll p r o life r a tio n e GNF4877 4 3 G N F 7 1 5 6 C h iro n 9 9 2 1 2 Insulin/Ki67
More informationPhospholipase C γ Prof. Graham Carpenter
Graham Carpenter, h.d. rofessor of Biochemistry Cornelia Crooke Department of Biochemistry Vanderbilt University School of Medicine, Nashville, TN 1 Receptor Tyrosine Kinases GF Extracellular M Intracellular
More informationAntibodies. Product Name Cat. No. Size. GH (Growth Hormone) Antibody µg, 100 µg GM-CSF Antibody µg, 100 µg
JAK/STAT Signaling The JAK/STAT signaling pathway transmits a signal from outside the cell eventually resulting in DNA transcription and activity in the cell. Leptin (a product of the obese gene) can induce
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/8/364/ra18/dc1 Supplementary Materials for The tyrosine phosphatase (Pez) inhibits metastasis by altering protein trafficking Leila Belle, Naveid Ali, Ana Lonic,
More informationTHE HALLMARKS OF CANCER
THE HALLMARKS OF CANCER ONCOGENES - Most of the oncogenes were first identified in retroviruses: EGFR (ErbB), Src, Ras, Myc, PI3K and others (slightly more than 30) - Mutated cellular genes incorporated
More information